Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar + camrelizumab + chemotherapy as first-line treatment for driver-negative advanced NSCLC
ChiCTR2100046535Phase 2Recruiting
- Sponsor
- First Hospital of Nanping
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of endostar and camrelizumab in non-small cell lung cancer (NSCLC), sponsored by First Hospital of Nanping. Primary endpoint: progression-free survival. Started Jun 2021; status: recruiting.
02
Drugs
endostarcamrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100046535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046535.